Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

MT-302 (A)

Phase 1Small molecule

MMyeloid Therapeutics

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Epithelial TumorRecruiting

Epithelial TumorPhase 1

Recruiting

Timeline

Expected Milestones

Q3 2028

Phase 1Recruiting

Epithelial Tumor

NCT05969041

Clinical

Trials by Indication[1]

Epithelial Tumor1 trial

Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors

Recruiting·MMyeloid Therapeutics·Phase 1·NCT05969041·48 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for MT-302 (A). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MT-302 (A) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MT-302 (A). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Myeloid Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: MMyeloid Therapeutics

Related News